Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AO 176

Next Previous
Search
Drug Profile

AO 176

Alternative Names: AO-176

Latest Information Update: 04 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arch Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; Cell death stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Solid tumours
  • Preclinical Diffuse large B cell lymphoma; Lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Feb 2023 Arch Oncology in collaboration with Merck Sharp & Dohme LLC completes the phase-I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT03834948)
  • 21 Jan 2022 AO 176 receives orphan drug designation for multiple myeloma in USA
  • 11 Dec 2021 Preclinical trials in Diffuse large B cell lymphoma in USA (Parenteral) prior to December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top